More biotech and health care stories
RHODE MAP
An intriguing new charter school proposal
The R.I. Medical Society wants to open a school to prepare marginalized 7th and 8th graders - and eventually high schoolers - for careers in medicine.
Evelo Biosciences, a microbiome company launched by Flagship, shuts down
The Cambridge biotech is ceasing operations after running low on cash and seeing multiple drug trial failures.
How to pass the holiday stress test
Despite the best of intentions and preparations, life can still spin out of control during the season.
OxyContin maker’s settlement plan divides victims of opioid crisis. Now it’s up to the Supreme Court.
The issue for the justices is whether the legal shield that bankruptcy provides can be extended to people such as the Sacklers, who have not declared bankruptcy themselves.
‘It’s a very human condition’: Researchers seek answers to mystery of autism, in blood
A campaign aims to get more people with autism to provide blood samples for research.
Harvard University researchers discover one of the origins of itch
The key lies in a common bacteria found on the skin.
Merck buys small Cambridge biotech for up to $610 million
Caraway Therapeutics is developing medicines to treat conditions such as Parkinson’s disease, ALS, and rare kidney diseases.
Flagship Pioneering launches new biotech with Mass., UK offices
Quotient Therapeutics, which will have offices in Mass. and the United Kingdom, wants to develop drugs that target illnesses caused by genetic changes that occur as people age.